Lorcaserin

Lorcaserin
Clinical data
Trade names	Belviq
Other names	APD-356
AHFS/Drugs.com	Monograph
MedlinePlus	a613014
License data	US DailyMed: Lorcaserin; US FDA: Lorcaserin;
Routes of; administration	Oral
ATC code	A08AA11 (WHO) ;
Legal status
Legal status	US: Schedule IV / Withdrawn;
Pharmacokinetic data
Protein binding	70%
Metabolism	Hepatic (extensive)
Elimination half-life	11 hours
Excretion	Renal (92.3%), Faecal (2.2%)
Identifiers
	IUPAC name (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;
CAS Number	616202-92-7 ;
PubChem CID	11658860;
IUPHAR/BPS	2941;
DrugBank	DB04871;
ChemSpider	9833595 ;
UNII	637E494O0Z;
ChEBI	CHEBI:65353;
ChEMBL	ChEMBL360328 ;
CompTox Dashboard (EPA)	DTXSID3048659 ;
ECHA InfoCard	100.237.138
Chemical and physical data
Formula	C11H14ClN
Molar mass	195.69 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1CNCCC2=C1C=C(C=C2)Cl;
	InChI InChI=1S/C11H14ClN/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9/h2-3,6,8,13H,4-5,7H2,1H3/t8-/m0/s1 ; Key:XTTZERNUQAFMOF-QMMMGPOBSA-N ;
	(verify)

Lorcaserin, marketed under the brand name Belviq, was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT_2C receptor in the hypothalamus, a region of the brain which is known to control appetite. It was approved in 2012, and in 2020, it was removed from the market in the United States due to an increased risk of cancer detected in users of Belviq.